The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study

M Trojano; Pesch V Van; Roughani R Al; A Rovira; G Cutter; D Dzhenkova; N Hagenbuch; R Kantaria; L Craveiro; J Hobart

doi:10.1111/ene.15466

The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study

M Trojano, Pesch V Van, Roughani R Al, A Rovira, G Cutter, D Dzhenkova, N Hagenbuch, R Kantaria, L Craveiro, J Hobart

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1111/ene.15466
Publication status	Published - Jul 2022

Access to Document

10.1111/ene.15466

Cite this

@conference{73c63a0c20c34d0d93cd681e6b71cb34,

title = "The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study",

author = "M Trojano and Van, {Pesch V} and Al, {Roughani R} and A Rovira and G Cutter and D Dzhenkova and N Hagenbuch and R Kantaria and L Craveiro and J Hobart",

year = "2022",

month = jul,

doi = "10.1111/ene.15466",

language = "English",

}

TY - CONF

T1 - The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study

AU - Trojano, M

AU - Van, Pesch V

AU - Al, Roughani R

AU - Rovira, A

AU - Cutter, G

AU - Dzhenkova, D

AU - Hagenbuch, N

AU - Kantaria, R

AU - Craveiro, L

AU - Hobart, J

PY - 2022/7

Y1 - 2022/7

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000815254003089&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1111/ene.15466

DO - 10.1111/ene.15466

M3 - Conference paper (not formally published)

ER -

The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study

Access to Document

Other files and links

Cite this